CTLA4 and neoplasm: Early treatment with anti-CTLA4, but not with anti-PD-L1 or anti-RL, significantly attenuated RANK−/− tumor growth (66.7% of implanted tumors did not grow) compared with the isotype-treated control (Fig. 4d).